Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.
This report will:
- Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future
- Explore what’s next for antibody-based drugs and where the opportunity is coming from
- Include an interview Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery
- Share significant future trends for the therapeutic antibody market
Key insights:
- The global mAb market size was valued at $185.50 billion in 2021
- Biopharmas originating in China will likely have greater influence on the industry by 2028
- The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community
- With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America
- Of the total number of antibody drugs approved worldwide, 93% were approved first by four drug regulatory agencies: the FDA, EMA, PMDA and NMPA
